Skip to main content
SpringerLink
Log in

IFN-γ in der Behandlung der systemischen Sklerodermie — Ergebnisse einer kontrollierten Multicenter-Studie

  • Conference paper
Dermatologie

  • 148 Accesses

Zusammenfassung

Die systemische Sklerodermie ist eine bislang schwer therapierbare Multisystemerkrankung, die neben der Haut auch innere Organe wie Lunge, Gastrointestinal- trakt, Herz, Nieren und Gelenke betreffen kann. Weithin akzeptiert wird ein Konzept der Pathogenese, das vasculäre und immunologische Prozesse an den Beginn der Kaskade stellt und die Fibrose als Ergebnis komplexer Zell-, Zytokin- und Adhäsionsmolekülinteraktionen sieht.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Arbeitsgruppe Sklerodermie“ der Arbeitsgemeinschaft Dermatologische Forschung (ADF) (1086) Klinik der pro¬gressiven systemischen Sklerodermie (PSS). Multizentrische Untersuchungen an 194 Patienten. Hautarzt 6/37: 320–324

    Google Scholar 

  2. Clements PJ, Medsger TA Jr (1996) Organ involvement: skin. In: Clements PJ, Fürst DE (eds) Systemic Sclerosis. Williams & Wilkins, Baltimore, pp 389–407

    Google Scholar 

  3. Clements PJ (1995) Measuring disease activity and severity in scleroderma. Curr Opinion Rheumatol 7: 517–521

    Article  CAS  Google Scholar 

  4. Dau PC, Kahaleh MB, Sagabiel RW (1981) Plasmapheresis and immunosuppressive drug therapy in scleroderma. Arthritis Rheum 24: 1128–1136

    Article  PubMed  CAS  Google Scholar 

  5. Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, Weinstein A, Weisman M, Mayes M, Collier D, Wigley F, Medsger T Jr, Steen V, Moreland L, Dixon M, Massa M, Lally E, McCloskey D, Varga J, Ingenito F, Fürst D (1995) Inter- and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 22: 1281–1285

    PubMed  CAS  Google Scholar 

  6. Clements PJ, Fürst DJ, Seibold JR, Lachenbruch PA (1996) Controlled trials: Trial design issues. In: Clements PJ, Fürst DE (eds) Systemic Sclerosis. Williams & Wilkins, Baltimore, pp 389–407

    Google Scholar 

  7. Farmer RG, Gifford RW Jr, Hines EA Jr (1960) Prognostic significance of Raynaud’s phenomenon and other clinical cha¬racteristics of systemic scleroderma. A study of 271 cases. Circulation 21: 1088–1095

    PubMed  CAS  Google Scholar 

  8. Fierlbeck G, Rassner G (1988) Rekombinantes Interferon- gamma bei Psoriasis arthropathica, progressiv systemischer Sklerodermie und Morbus Behcet. Med Klinik 21: 695–699

    Google Scholar 

  9. Freundlich B, Jimenez SA, Steen VD, Medsger TA Jr, Szkolnicki M, Jaffe HS (1992) Treatment of systemic sclerosis with recombinant interferon-g. Arthritis and Rheumatism 35: 1134–1142

    Article  PubMed  CAS  Google Scholar 

  10. Hein R, Behr J, Hündgen M, Hunzelmann N, Meurer M, Braun-Falco O, Urbanski A, Krieg T (1992) Treatment of systemic sclerosis with g-interferon. Brit J Dermatol 126: 496–501

    Article  CAS  Google Scholar 

  11. Jimenez SA, Sigal H (1989) A fifteen year prospective study of treatment of rapid progressive systemic sclerosis (PSS) with D-penicillamine (D-pen). Arthritis Rheum 32 (suppl): A134

    Google Scholar 

  12. Kahan A, Amor B, Menkes CJ, Stauch G (1989) Recombinant interferon gamma in the treatment of systemic sclerosis. Am J Med 87: 273–277

    Article  PubMed  CAS  Google Scholar 

  13. Pope J (1993) Treatment of systemic sclerosis. Curr Opinion Rheumatol 5: 792–801

    Article  CAS  Google Scholar 

  14. Rodnan GP, Lipinski E, Luksick J (1979) Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 22: 130–140

    Article  PubMed  CAS  Google Scholar 

  15. Rosenbloom J, Feldman G, Freundlich B, Jimenez SA (1986) Inhibition of excessive scleroderma fibroblast collagen pro¬duction by recombinant g-interferon: association with a coordinate decrease in types I and III procollagen messenger RNA levels. Arthritis Rheum 29: 851–856

    Article  PubMed  CAS  Google Scholar 

  16. Seibold JR, Fürst DE, Clements PJ (1996) Treatment of systemic sclerosis by disease modifying agents. In: Clements PJ, Fürst DE (eds)Systemic Sclerosis. Williams 8c Wilkins, Baltimore, pp 535 –548

    Google Scholar 

  17. Steen VD (1996) Organ involvement: renal. In: Clements PJ, Fürst DE (eds)Systemic Sclerosis. Williams & Wilkins, Baltimore, pp 389–407

    Google Scholar 

  18. Steen VD, Medsger TA, Rodnan GP (1982) D-Penicillamine therapy in systemic progressive sclerosis (scleroderma). A retrospective analysis. Ann Int Med 97: 652–659

    PubMed  CAS  Google Scholar 

  19. Stevens W, Vancheeswaran R, Black CM, UK Systemic Sclerosis Study Group. Alpha interferon-2a (Roferon-A) in the treatment of diffuse cutaneous systemic sclerosis: a pilot study. British J Rheumatol 31: 683–689

    Google Scholar 

Download references

Authors
  1. A. Grassegger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Schuler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Hessenberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. O. Fritsch
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hautklinik, Universitätsklinikum Tübingen, Liebermeisterstraße 25, D-27076, Tübingen, Deutschland

    C. Garbe  & G. Rassner  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Grassegger, A., Schuler, G., Hessenberger, G., Fritsch, P.O. (1998). IFN-γ in der Behandlung der systemischen Sklerodermie — Ergebnisse einer kontrollierten Multicenter-Studie. In: Garbe, C., Rassner, G. (eds) Dermatologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71974-5_40

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-71974-5_40

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-71975-2

  • Online ISBN: 978-3-642-71974-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation